Dr. Helge Lubenow
Dr. Helge Lubenow (*1968, German) studied Biology and earned the doctoral degree at the University of Cologne and the Max-Planck-Institute in the field of genetics.
After joining Qiagen GmbH, Germany, in 1997, Dr. Lubenow held various positions, including Senior Vice President and head of molecular diagnostic business (2011 to 2015). During this time, Dr. Lubenow assumed positions in enterprises newly acquired by Qiagen GmbH, such as Corbett Life Science, Sydney and Brisbane, Australia and Digene Inc., Gaithersburg, U.S.A. and was responsible for restructuring or integration of the respective enterprise. In 2016, Dr. Lubenow founded her own consulting firm AGOS Consulting. From 2018 to 2019 she was the managing director of tesa Labtec GmbH. In January 2020 she was appointed as CEO of Proteomedix AG, Zurich, Switzerland, an organization which she had served as a member of the Verwaltungsrat since 2017.
Dr. Lubenow has been a Supervisory Board member of Epigenomics AG since June 2016. She is an independent member (within the meaning of the German Corporate Governance Code). Dr. Lubenow’s current appointment ends in 2024.
Dr. Lubenow is not a member of other legally required supervisory boards. She is a member of comparable control committees of the following commercial enterprises: Indical Biosciences GmbH, Leipzig, Germany and Tesa Labtec GmbH, Germany.